Physician profile
Michael E Perry
NPI 1356385470
$12,506.89
in general payments reported to CMS, 2019-2025
30 companies · $3,208 in 2025
The $3,208 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,822 · 2022: $1,646 · 2023: $2,839 · 2024: $2,991 · 2025: $3,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,966 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,966.30 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,156.60 | 2021-2025 | |
| Janssen Biotech, INC. | $2,086.09 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Leo Pharma INC. | $1,174.91 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $936.29 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $777.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $428.20 | 2021-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $390.26 | 2021-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $390.13 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $365.87 | 2021-2025 | |
| Amgen INC. | $362.11 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $342.69 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $339.89 | 2022-2025 | |
| Incyte Corporation | $330.98 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $324.40 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $208.72 | 2021-2025 | Nemluvio, Aklief, Oracea |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $149.47 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Almirall LLC | $131.76 | 2021-2025 | Seysara, Klisyri |
| Ucb, INC. | $130.04 | 2021-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $117.94 | 2021 | |
| Organon LLC | $98.34 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $48.66 | 2023-2024 | Zoryve |
| Lnhc, INC | $33.74 | 2025 | Zelsuvmi |
| Hill Dermaceuticals, INC. | $33.34 | 2023 | Tolak |
| Botanix Sb INC | $28.06 | 2025 | Sofdra |
| Journey Medical Corporation | $23.58 | 2023 | |
| Verrica Pharmaceuticals INC. | $23.46 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.24 | 2023 | Spevigo |
| Sanofi-Aventis U.S. LLC | $21.84 | 2021 | |
| Hologic Sales and Service, LLC | $16.02 | 2024 | Fluent Fluid Management System |
| Dermira, INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.